Who are AGN-199201 ophthalmic solution's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): latanoprost 0.005% (drug), Preservative-free latanoprost 50µg/ml, latanoprost 0.005% (Xalatan), Tafluprost 15µg/ml, travoprost, latanoprost, or bimatoprost, APP13007, 0.05%.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/agn-199201-ophthalmic-solution.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

AGN-199201 ophthalmic solution — Competitive Intelligence Brief

AGN-199201 ophthalmic solution (AGN-199201 ophthalmic solution) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Prostaglandin F receptor agonist. Area: Ophthalmology.

phase 2 Prostaglandin F receptor agonist FP receptor (prostaglandin F receptor) Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

AGN-199201 ophthalmic solution (AGN-199201 ophthalmic solution) — Allergan. AGN-199201 is a selective prostaglandin F (FP) receptor agonist that increases uveoscleral outflow of aqueous humor to reduce intraocular pressure.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
AGN-199201 ophthalmic solution TARGET	AGN-199201 ophthalmic solution	Allergan	phase 2	Prostaglandin F receptor agonist	FP receptor (prostaglandin F receptor)
latanoprost 0.005% (drug)	latanoprost 0.005% (drug)	University Hospital, Basel, Switzerland	marketed	Prostaglandin F receptor agonist	FP receptor (prostaglandin F receptor)
Preservative-free latanoprost 50µg/ml	Preservative-free latanoprost 50µg/ml	Medical University of Vienna	marketed	Prostaglandin F receptor agonist	FP receptor (prostaglandin F receptor)
latanoprost 0.005% (Xalatan)	latanoprost 0.005% (Xalatan)	Pfizer	marketed	Prostaglandin F receptor agonist	FP receptor (prostaglandin F receptor)
Tafluprost 15µg/ml	Tafluprost 15µg/ml	Ordination Dr. Hommer	marketed	Prostaglandin F receptor agonist	FP receptor (prostaglandin F receptor)
travoprost, latanoprost, or bimatoprost	travoprost, latanoprost, or bimatoprost	Robin, Alan L., M.D.	marketed	Prostaglandin F receptor agonist	FP prostaglandin receptor
APP13007, 0.05%	APP13007, 0.05%	Formosa Pharmaceuticals, Inc.	phase 3	Prostaglandin F receptor agonist	FP receptor (prostaglandin F receptor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Prostaglandin F receptor agonist class)

Allergan · 2 drugs in this class
Formosa Pharmaceuticals, Inc. · 1 drug in this class
Medical University of Vienna · 1 drug in this class
Ordination Dr. Hommer · 1 drug in this class
Pfizer · 1 drug in this class
Robin, Alan L., M.D. · 1 drug in this class
University Hospital, Basel, Switzerland · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AGN-199201 ophthalmic solution — Competitive Intelligence Brief. https://druglandscape.com/ci/agn-199201-ophthalmic-solution. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab